ARLINGTON, VA / ACCESS Newswire / August 13, 2025 / FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into the FriskaAi platform. Under the agreement, data from Dexcom CGMs will be integrated with Friska Ai, the company’s groundbreaking AI-powered healthcare platform supporting physicians and patients with actionable personalized care management programs.
FriskaAi is a physician-directed health and wellness platform that supports the management of diabetes and other chronic diseases by helping providers take an evidence-based approach to preventive care. The EHR-agnostic FriskaAi platform leverages advanced AI and mobile technology to generate personalized health insights and recommendations, empowering patients to take control of their health journey in partnership with their clinical team.
“Impacting more than 38 million Americans, diabetes has emerged as a major public health problem, and its effective management has become a foundational element of preventive medicine,” says Shaji Nair, CEO of FriskaAi. “Dexcom’s pioneering CGMs are vital tools not only for diabetes management but also for informing broader care decisions. FriskaAi is excited about the potential this integration with Dexcom presents to the physicians relying on our platform for chronic disease management and the patients seeking greater control over their health and wellness.”
Dexcom CGMs use a small, wearable sensor to continuously measure and send glucose levels wirelessly to a smart device or receiver in real-time, without the need for fingerpricks. Dexcom CGMs also offer a suite of customizable alerts that can warn of high or low glucose levels and send predictive alerts to help users spend more time in range.
The FriskaAi mobile app securely integrates with Dexcom CGMs and other smart devices, as well as health apps, for analysis by the powerful HIPAA-compliant FriskaAi platform. That data, along with other clinical data and studies, is continuously monitored by sophisticated AI-powered algorithms that alert the patient when action is recommended and generate actionable reports for use by the clinician at the point of care to inform care decisions.
Aggregated health data is also analyzed within the FriskaAI platform to help physicians identify trends and risks within their patient populations, enabling more proactive and preventive care strategies.
About FriskaAi
FriskaAi is a powerful AI-enabled EHR-agnostic platform that helps physicians and other providers take an evidence-based approach to preventive care. The physician-initiated platform leverages advanced AI- and mobile technology to provide patients with personalized health insights and recommendations, empowering them to take control of their health journey in partnership with their clinical team. This aggregated health data, including information from patients’ glucometers, other smart devices, and health apps, is continuously analyzed by advanced evidence-based algorithms that alert the patient when action is needed and provide clinicians with actionable reports to inform care decisions. FriskaAi also supports population health strategies by analyzing aggregated health data to identify trends and risks within a defined patient population. For more information, visit www.friska.ai.
Media Contact: Michele Nachum NPC Creative Services michele@npccs.com
BROOKLYN, NY / ACCESS Newswire / August 13, 2025 / IEH Corporation (OTC:IEHC) yesterday filed with the Securities and Exchange Commission (SEC) its quarterly report on Form 10-Q for the 1st fiscal quarter ended June 30, 2025.
Highlights include:
11% Decrease in Revenue as compared to first quarter of Fiscal Year 2025
$755,306 loss in Operating Income
Cash 43% higher than first quarter of Fiscal Year 2025
Backlog increase of 25% since beginning of Fiscal Year 2026
Over $2.5 million in orders supporting missile defense programs booked in recent weeks
For the quarter ended June 30, 2025, IEH had revenues of $6,308,155 as compared to $7,104,977 for the quarter ended June 30, 2024 reflecting an 11% decrease; an operating loss of $755,306 for 1st quarter fiscal year 2026 as compared to an operating gain of $332,979 for 1st quarter fiscal year 2025; a net loss of $654,618 for 1st quarter fiscal year 2026 as compared to a net gain of $392,787 for 1st quarter fiscal year 2025; and a basic loss per share of $.27 for 1st quarter fiscal year 2026 as compared to a basic gain per share of $.17 for 1st quarter fiscal year 2025.
Dave Offerman, President and CEO of IEH Corporation commented, “As forecasted in prior communications, while our long-term trajectory continues to trend upwards, our results from one quarter to the next may be uneven. This is reflected in our first quarter, as revenue was lower than the last few quarters due primarily to customer schedule delays, along with the still slow recovery of the commercial aircraft sector.
However, the long-term projections, especially in our largest sector, defense, remain strong. Indeed, we recently booked over $2.5 million in orders in support of various missile defense programs, including PATRIOT, AMRAAM, LTMADS and others. Our sales pipeline indicates more orders are on the horizon. Our commercial space launch business continues to grow, and we continue to eagerly anticipate a return to pre-COVID levels of business in the commercial aerospace sector. Initiatives to grow our product lines and markets served via organic and inorganic growth continue, and we look forward to sharing more good news in the coming quarters.
On behalf of the management team and staff of IEH, we again wish to express our sincere gratitude for the support of our valued shareholders.”
About IEH Corporation
For over 80 years and 4 generations of family-run management, IEH Corporation has designed, developed, and manufactured printed circuit board (PCB) connectors, custom interconnects and contacts for high performance applications. With its signature Hyperboloid technology, IEH supplies the most durable, reliable connectors for the most demanding environments. The Company markets primarily to companies in defense, aerospace, medical, space and industrial applications, in the United States, Canada, Europe, Southeast and Central Asia and the Mideast. The Company was founded in 1941 and is headquartered in Brooklyn, New York.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this press release, and in related comments by the Company’s management, include “forward-looking statements.” All statements, other than statements of historical facts, including, without limitation, statements or expectations regarding our financial condition, statements or expectations regarding our revenues, cash and backlog, expectations regarding future cash requirements, revenue and revenue recovery, including for fiscal year 2026 and beyond, projected timelines for making our SEC filings or successfully preventing our registration from suspension or revocation and expectations regarding our efforts and ability to resolve our inventory accounting issues are forward-looking statements. These statements often include words such as “believe,” “expect,” “estimate,” “plan,” “will,” “may,” “would,” “should,” “could,” or similar expressions, although not all forward-looking statements contain such identifying words. These statements are based on certain assumptions that the Company has made on its current expectations and projections about future events. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance or results, and you should not place undue reliance on any forward-looking statements. The Company’s actual performance or results could differ materially from those expressed in the forward-looking statements due to a variety of important factors, both positive and negative, as they will depend on many factors about which we are unsure, including many factors beyond our control. Among other items, such factors could include: any claims, investigations or proceedings arising as a result of our past due periodic reports, including changes in the proceedings related to the SEC’s Order Instituting Administrative Proceedings and Notice of Hearing pursuant to Section 12(j) of the Securities and Exchange Act of 1934, as amended; our ability to remediate our inventory accounting issue; our ability to reduce costs or increase revenue; changes in the macroeconomic environment or in the finances of our customers; changes in accounting principles, or their application or interpretation, and our ability to make accurate estimates and the assumptions underlying the estimates; our ability to attract and retain key employees and key resources; and other risk factors discussed from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on June 12, 2025, and in subsequent reports filed with or furnished to the SEC. Additional information concerning these and other factors can be found in our filings with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this press release as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in our filings with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.
XCF Global and OpenSponsorship partner to provide sports, entertainment, and music industries with carbon-neutral air travel opportunities
Initiative drives awareness around reducing aviation emissions by offering a practical carbon offset solution
Partnership empowers athletes, entertainers, and musicians to leverage their platforms to promote positive societal change
HOUSTON, TEXAS / ACCESS Newswire / August 13, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a key player in decarbonizing the aviation industry through Synthetic Aviation Fuel (“SAF”) today announces a strategic partnership with OpenSponsorship Corp. (“OpenSponsorship”), a New York-based marketing agency specializing in sponsorships for sports and entertainment industries to drive awareness for carbon-neutral air travel. This campaign creates unique opportunities for sports teams, actors and actresses, and musicians to participate in carbon-neutral travel activities, raising awareness around the decarbonization of air travel.
As part of the partnership, XCF will offer a comprehensive carbon offset solution for sports and entertainment travel, ensuring that flights to games,tournaments, concerts, and other events are fully carbon neutral. Such sponsorships aim to demonstrate a practical and impactful approach to sustainability, contributing to the global movement toward reducing emissions from the aviation industry.
Mihir Dange, CEO and Board Chair of XCF Global commented:
“We are thrilled to partner with OpenSponsorship and bring carbon-neutral travel opportunities to sports, entertainment, and music industries. This partnership enables high-profile individuals and organizations to meaningfully engage with their audiences by showcasing their leadership in sustainability and driving awareness of the need to decarbonize the aviation industry. Together, we’re turning the spotlight on the urgent need to decarbonize the aviation industry and providing a clear path for others to follow.”
OpenSponsorship is revolutionizing the sponsorship landscape by simplifying the connection between brands and talent in the sports, entertainment, and music industries. Their platform provides brands of all industries with streamlined access to the benefits of sports and entertainment sponsorships, empowering them to engage with talent and athletes through mutually beneficial partnerships.
OpenSponsorship Founder and CEO, Ishveen Jolly said:
“We’re excited to work with XCF to bring carbon-neutral travel to the forefront of sports and entertainment sponsorships. Athletes, musicians, and actors hold immense influence, and their global followings make them powerful advocates for change. This partnership empowers them to lead by example, using their platforms to inspire fans and effect positive societal change.”
XCF Global, Inc. is a pioneering synthetic aviation fuel company dedicated to accelerating the aviation industry’s transition to net-zero emissions. XCF is developing and operating state-of-the-art clean fuel SAF production facilities engineered to the highest levels of compliance, reliability, and quality. The company is actively building partnerships across the energy and transportation sectors to accelerate the adoption of SAF on a global scale. XCF is listed on the Nasdaq Capital Market and trades under the ticker, SAFX. Current outstanding shares: ~149.3 million; 20% free float (as of August 13, 2025).
This Press Release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements, including, without limitation, statements regarding XCF Global’s expectations with respect to future performance and anticipated financial impacts of the recently completed business combination with Focus Impact BH3 Acquisition Company (the “Business Combination”), estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share, are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by XCF Global and its management, are inherently uncertain and subject to material change. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in domestic and foreign business, market, financial, political, and legal conditions; (2) unexpected increases in XCF Global’s expenses resulting from potential inflationary pressures and rising interest rates, including manufacturing and operating expenses and interest expenses; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any agreements with regard to XCF Global’s offtake arrangements; (4) the outcome of any legal proceedings that may be instituted against the parties to the Business Combination or others; (5) XCF Global’s ability to meet Nasdaq’s continued listing standards; (6) XCF Global’s ability to integrate the operations of New Rise and implement its business plan on its anticipated timeline; (7) XCF Global’s ability to raise financing in the future and the terms of any such financing; (8) the New Rise Reno production facility’s ability to produce the anticipated quantities of SAF without interruption or material changes to the SAF production process; (9) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its landlord with respect to the ground lease for the New Rise Reno facility; (10) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its primary lender with respect to loans outstanding that were used in the development of the New Rise Reno facility; (11) costs related to the Business Combination and the New Rise acquisitions; (12) the risk of disruption to the current plans and operations of XCF Global as a result of the consummation of the Business Combination; (13) XCF Global’s ability to recognize the anticipated benefits of the Business Combination and the New Rise acquisitions, which may be affected by, among other things, competition, the ability of XCF Global to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (14) changes in applicable laws or regulations; (15) risks related to extensive regulation, compliance obligations and rigorous enforcement by federal, state, and non-U.S. governmental authorities; (16) the possibility that XCF Global may be adversely affected by other economic, business, and/or competitive factors; (17) the availability of tax credits and other federal, state or local government support; (18) risks relating to XCF Global’s and New Rise’s key intellectual property rights; (19) the risk that XCF Global’s reporting and compliance obligations as a publicly-traded company divert management resources from business operations; (20) the effects of increased costs associated with operating as a public company; and (21) various factors beyond management’s control, including general economic conditions and other risks, uncertainties and factors set forth in XCF Global’s filings with the Securities and Exchange Commission (“SEC”), including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF Global makes with the SEC in the future. If any of the risks actually occur, either alone or in combination with other events or circumstances, or XCF Global’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that XCF Global does not presently know or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XCF Global’s expectations, plans or forecasts of future events and views as of the date of this Press Release. These forward-looking statements should not be relied upon as representing XCF Global’s assessments as of any date subsequent to the date of this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements. While XCF Global may elect to update these forward-looking statements at some point in the future, XCF Global specifically disclaims any obligation to do so.
RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today announced a significant expansion of its intellectual property portfolio for TH-104, its novel transmucosal film. The new patents, recently granted and allowed across key global markets, will enable the Company’s long-term strategy of pursuing broader indications for the technology, beginning with its lead program as a critical medical countermeasure for military and first responders against high-potency opioids.
This announcement follows recent positive feedback from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) pathway for TH-104. The FDA confirmed that a 505(b)(2) NDA submission for the prevention of respiratory and/or central nervous system distress is a viable path, and no additional clinical trials seem to be required for this specific indication for use in military personnel and/or first responders who may be exposed to weaponized high-potency opioids, such as fentanyl or its analogues. This positive feedback, combined with the appointment of counter-terrorism expert James Liddy to the Board of Directors, accelerates the Company’s efforts to position TH-104 as a national security solution.
The recent granting and allowance of patents in Japan, Mexico, Australia, and the United States further strengthen the Company’s intellectual property position, providing protection for TH-104 out to at least 2040 in key markets. While the initial focus is on military and first responders, these patents are foundational for addressing other significant medical needs to combat pruritus, a debilitating form of itch associated with certain chronic liver and kidney diseases.
TH-104 is a buccal film formulation of nalmefene, an opioid antagonist with a significantly longer half-life compared to existing options of autoinjectors and other formulations containing the active ingredient of products such as Narcan®. This extended duration may provide sustained protection, which is crucial for personnel operating in high-risk environments where repeated dosing may not be feasible.
“The recent patent grants are important for our TH-104 platform,” said Sireesh Appajosyula, CEO of Tharimmune. “This is a dual achievement which validates our innovative drug delivery technology and secures the long-term potential of TH-104 to address multiple high-impact indications. While we are prioritizing its role as a life-saving medical countermeasure for our military and first responders, this patent portfolio provides a runway to develop our lead candidate for other debilitating conditions where there is a significant unmet medical need.”
The newly granted and allowed patents specifically cover a novel method and device for transmucosal administration of nalmefene via a single-layer, self-supporting, mucoadhesive film with distinct domains for optimized drug delivery and pH balance.
The granted and allowed patents include:
United States (US) Application No. 17/285,971 (Allowed)
Japan (JP) Patent No. 7603583 (Granted)
Mexico (MX) Patent No. 422769 (Granted)
Australia (AU) Patent Application No. 2019361980 (Allowed)
Tharimmune is dedicated to advancing TH-104 to provide a potentially effective and patient-friendly treatment as an option for those in need, beginning with its critical role in national security.
About Tharimmune, Inc.
Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune’s future Phase 2 trial, Tharimmune’s strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. Subsequent events and developments may cause the Company’s views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.
Industry experts warn that payroll mistakes are becoming a leading cause of tax penalties for small business owners in 2025.
IRVINE, CALIFORNIA / ACCESS Newswire / August 13, 2025 / A growing number of small business owners are facing costly penalties from the Internal Revenue Service (IRS) due to payroll errors, according to recent industry data. With changing regulations, new digital filing requirements, and heightened IRS enforcement, experts say payroll missteps are more than just bookkeeping blunders – they can become expensive liabilities.
“Payroll isn’t just about paying employees on time – it’s about paying the right taxes, to the right agencies, at the right time,” said a spokesperson for Clear Start Tax, a national tax relief and resolution firm. “We’re seeing an uptick in IRS penalties for businesses that underreport, misclassify employees, or miss deposit deadlines, and the financial fallout can be devastating.”
Common mistakes include misclassifying workers as independent contractors instead of employees, failing to deposit withheld taxes promptly, and overlooking quarterly filing requirements. These errors can lead to penalties, interest charges, and in some cases, IRS liens or levies.
Clear Start Tax warns that the IRS has increased its use of automated systems to flag payroll inconsistencies.
“Business owners need to understand that payroll taxes are one of the IRS’s top collection priorities,” the spokesperson added. “Once a payroll issue is identified, the clock starts ticking, and penalties can snowball quickly.”
To help business owners stay compliant, Clear Start Tax recommends:
Double-checking worker classification to ensure IRS guidelines are met.
Scheduling automated tax deposits to avoid missed deadlines.
Reconciling payroll reports with tax filings each quarter.
Consulting a tax professional before making major payroll changes.
By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.
“Proactive compliance is the best defense,” said the spokesperson. “A small oversight today can turn into a major problem six months from now. The businesses that survive and thrive are the ones that get ahead of these issues before the IRS gets involved.”
About Clear Start Tax Clear Start Tax is a nationwide tax resolution and relief firm specializing in helping individuals and businesses address IRS and state tax issues. With a team of experienced tax professionals, the company provides tailored strategies for resolving back taxes, negotiating settlements, and achieving long-term compliance.
BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential
30,000 BUZZ BOMB™ sample packs of four 50mg stick packs in each flavor distributed to convention attendees
Well-known fitness instructors, fitness celebrities, athletes, and influencers along with thousands of fitness enthusiasts and consumers sampled BUZZ BOMB™’s four bold flavors
As part of its launch, Aspire plans on partnering with well-known athletes and influencers across fitness training and endurance sports to accelerate consumer awareness and uptake
BUZZ BOMB™ is available for purchase at buzzbomb.buzz, the Company’s new E-commerce website
ESTERO, FL / ACCESS Newswire / August 13, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending supplement delivery technology, today announced the successful launch and distribution of over 30,000 BUZZ BOMB™ sample four-packs, its newsublingual pre-workout supplement, at FitCon and FitExpo, held August 1-3, in Salt Lake City and Anaheim, with an estimated combined attendance in excess of 70,000 people.
BUZZ BOMB™, featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed. Unlike most pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB™ is sprinkled under the tongue right before or during a workout for immediate effect via direct delivery to the bloodstream.
BUZZ BOMB™ Testimonial from Leading Figures in the Fitness World
Bobby Maximus is a UFC fighter, Ju Jitsu Masters World Champion and fitness trainer. He has broken multiple power-endurance world records and is recognized as a leading figure in the fitness world. He starred in the recent feature film “Kill Shot” and is a best-selling Men’s Health author and a regular contributor to “Men’s Health” magazine (https://www.menshealth.com/author/214988/bobby-maximus/).
“In just about a minute, it feels like I drank a pre-workout 20 minutes ago.”
“The taste… phenomenal! I really like that.”
“I work out 2-3 times a day. One of the most inconvenient things is trying to time your pre workout drink 30 minutes before your workout. “
When I have a short window, I don’t want to wait 30 minutes until it kicks in. The ability to just ‘dump and go’ with Buzz Bomb, is powerful. It’s the convenience factor!
“I love the idea behind it! It helps me keep my caffeine intake down. Especially when you train 2 to 3 times a day.”
“You cannot find another pre work with 50 mgs of caffeine… and it works! I love it!”
Brandon “MidWest Kong” Copeland (pictured above, third to the right) embodies the strength of a champion and the heart of a hero. A Brazilian Jiu-jitsu Black Belt, Copeland dominated the Mixed Martial Arts scene from 2005 to 2014, showcasing tenacity and skill. Initiating the “I Stopped The Bully” campaign in 2011, he became a beacon against bullying, inspiring youth across schools and detention centers. Copeland excelled in the fitness industry, breaking records like bench pressing 225 pounds 81 consecutive times. A published children’s book author, he spreads messages of hope and community.
“I took the product! Let me say thank God! No heart flutter, no itchy sensation, no crash! I don’t need the hard stuff anymore…feels absolutely great! I had a great workout as well!”
Commenting on the BUZZ BOMB™ launch, Kraig Higginson, Interim Chief Executive Officer of Aspire, said, “The launch and consumer response to BUZZ BOMB™ at two of the major fitness conventions, from booth activity, product sampling, feedback, interest from fitness experts and influencers, and potential licensing partners, exceeded all of our high expectations.”
Higginson added, “With BUZZ BOMB™, we’re raising the bar for ease of use, performance and value in the multi-billion-dollar caffeine category. We focused on creating a formula that is fast-absorbing and built for athletes, fitness enthusiasts and consumers who demand clean, effective fuel without unnecessary fillers or compromise. With online sales commencing August 1, we are now focused on increasing our marketing, expanding our third-party manufacturing capabilities, and preparing for further discussions with potential licensing partners in the nutritional and supplement space that can help us drive increased consumer awareness and accelerate our revenue potential for BUZZ BOMB™.”
Consumers can purchase BUZZ BOMB™ online at buzzbomb.buzz
BUZZ BOMB™ Pre-workout Benefits:
Speed – works nearly immediately (less than 2 minutes) vs. 20-30 minutes
Convenience – easy to use single-use packets vs. mixing and measuring for beverages
Energy management – use as needed to precisely manage caffeine intake (50mg increments)
Single Safe Active Ingredient – well-known benefits and use of caffeine
A clean manageable Energy Boost
Low manufacturing & packaging costs – competitive pricing with high margin potential
Aspire’s BUZZ BOMB™ – Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market.
About Aspire Biopharma, Inc.
Headquartered in Estero, Fl., Aspire Biopharma has developed a patent-pending disruptive technology that can deliver supplements and drugs to the body rapidly and precisely with less negative impact to the system by going directly to the bloodstream and avoiding the gastrointestinal tract. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as “estimate,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “potential,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations
Rubix Life Sciences CEO Reginald Swift, Ph.D. joins as Chief Scientific Officer with responsibility to shape KIFFIK’s clinical strategy
PROVIDENCE, RI / ACCESS Newswire / August 13, 2025 / KIFFIK Biomedical, Inc. (“Kiffik”), a leader in interstitial fluid (ISF)-based diagnostics, today announced two new appointments to its leadership team. Healthcare development executive Rene Veloso joins as Chief Investment Officer (CIO) along with Dr. Reginald(Reggie) Swift who will serve as a fractional Chief Scientific Officer (CSO).
“The addition of Rene and Reggie to our already strong leadership team is a game-changer as we embark on our next chapter of growth,” said George Cagna, CEO of KIFFIK Biomedical. “Ensuring our R&D function is meeting the highest scientific standards, coupled with securing operating capital, empowers our team to bring next-generation ISF biomonitoring to partners and patients.”
As CIO, Rene will be responsible for securing capital investments from institutional partners that want to unlock the full potential of interstitial fluid real-time monitoring for a range of cancers and other diseases. Most recently, Rene was Senior Vice President at Locust Walk Partners, LLC where he led multiple high-profile M&A activities on behalf of biopharma clients.
Dr. Reginald Swift is the CEO of Rubix Life Sciences, a leader in aptamer-based precision medicine. As a fractional CSO for KIFFIK Dr. Swift will help shape clinical operations to ensure research and development activities meet the highest scientific standards. Earlier this year, KIFFIK and Rubix LS established a strategic partnership to advance next-generation ISF extraction technology.
About KIFFIK Biomedical
KIFFIK Biomedical is pioneering interstitial fluid (ISF)-based diagnostics, transforming disease detection and health monitoring with a needle-free, real-time approach. As a leader in ISF science and biomarker detection, we are redefining non-invasive diagnostics for oncology, therapeutic monitoring, and beyond.
Our proprietary and patented KIFFIK EXP platform unlocks the potential of ISF, providing high-precision, accessible, and patient-friendly solutions. Through strategic partnerships and cutting-edge research, KIFFIK is driving the future of precision medicine and advancing diagnostics that empower earlier detection and better health outcomes.
BARRIE, ON / ACCESS Newswire / August 13, 2025 / Abrams Towing, a trusted provider of professional towing services in Southern Ontario, has been named a 2025 Consumer Choice Award recipient in the category of Towing Services for the Barrie region. This recognition reflects Abrams’ longstanding commitment to safe, efficient, and dependable roadside assistance-backed by more than 40 years of industry experience.
With a reputation for fast response times and professional service, Abrams has grown from a one-man operation into Canada’s largest towing company. Today, the company provides 24/7 towing and roadside assistance to individuals, businesses, municipalities, and emergency services across key regions, including Barrie, Newmarket, Toronto, Mississauga, Ottawa, Durham Region, Oakville, Hamilton, London, Cambridge and Windsor.
Over Four Decades of Trusted Towing Experience
Abrams Towing has built its operations around reliability, expertise, and customer care. With a fleet of more than 160 state-of-the-art tow trucks and a team of certified operators, the company handles a wide range of towing and recovery needs-from light-duty and flatbed towing to heavy-duty recovery, accident cleanup, and winching.
“Our team understands that breakdowns and accidents are stressful,” says the Abrams Towing team. “That’s why we’ve built a model focused on responsiveness, safety, and customer care-no matter the size or scope of the job.”
24/7 Towing Services Across Southern Ontario
Abrams operates a 24/7 live dispatch system, ensuring timely service around the clock. With operators strategically located throughout Ontario, including in Barrie, the company is well-positioned to respond quickly in both urban and rural areas.
Abrams offers a comprehensive suite of services, including:
Private Property Towing
24/7 Emergency Towing
Long Distance Towing
Roadside Assistance
Lockouts
Boosts
Fuel Delivery
Tire Changes
Specialty Towing / Equipment Winching
Commercial Towing
Drivers arrive fully equipped to manage most issues on-site, helping minimize downtime and stress for customers.
“We take pride in being there for our customers when they need us most,” the team adds. “Whether someone is stranded on the highway or a commercial client needs reliable support, our priority is to respond quickly and professionally.”
Committed to Safety and Innovation Abrams places a strong emphasis on safety and operator training. All vehicles are equipped with GPS tracking, emergency lighting, and modern safety features to ensure compliant and secure towing. Operators follow strict safety protocols and receive ongoing education to stay aligned with industry standards.
To support long-term growth and environmental goals, Abrams has also invested in fleet upgrades and efficiency measures that reduce emissions and improve service delivery.
Serving Barrie and the Greater Region While Abrams has a large presence throughout Ontario, local teams-like the one in Barrie-are essential to delivering personalized, community-focused service. Their knowledge of local roads, traffic conditions, and regional infrastructure allows them to provide fast, effective support tailored to each area’s needs.
“This recognition reinforces the commitment we’ve made to every driver, fleet manager, and emergency responder we work with,” says the Abrams Towing team. “We’re honoured to serve the Barrie community and proud to be part of a network that prioritizes safety, speed, and service excellence.”
Recognition Backed by Independent Research The Consumer Choice Award is the only organization in North America that recognizes business excellence through a four-step, independent research process. This includes third-party surveys, consumer feedback analysis, and brand reputation evaluation within each local market.
Being named a Consumer Choice Award recipient means Abrams Towing has earned high marks for customer satisfaction and service quality from the people who matter most-their customers.
About Consumer Choice Award: Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.
WATERLOO, ON / ACCESS Newswire / August 13, 2025 / Mitchell Blackwell Parging & Masonry Inc., a family-run masonry specialist known for quality craftsmanship, has won the 2026 Consumer Choice Award in the Masonry category for the Waterloo Region. This award recognizes Mitchell Blackwell Parging & Masonry Inc.’s 11 years of service-building on a family legacy that spans nearly four decades-with a focus on quality, reliability, and exceptional value.
Established in 2014 by Mitchell Blackwell-and building on two generations of skilled bricklayers-the company has become a trusted name in Kitchener-Waterloo and surrounding areas. Their diverse portfolio ranges from foundation repair and parging finishes to chimney restoration, stone patios, tuckpointing, epoxy flooring, and decorative concrete work.
“Our foundation is built on family values,” says Mitchell Blackwell, founder. “With nearly four decades of combined experience, we approach every project-whether parging a foundation or restoring heritage brick-with precision, respect, and pride.”
Comprehensive Masonry & Parging Solutions Mitchell Blackwell Parging & Masonry offers a wide range of services designed to meet both aesthetic and structural needs:
Parging & Foundation Repair – Sand‑face, stone‑face, and custom finishes designed to enhance and protect foundations.
Brickwork & Stone Construction – Chimney and fireplace restoration, retaining walls, veneer stone, custom patio features, heritage brick repair, and tuckpointing.
Concrete & Epoxy Finishes – Durable coatings for garages, basements, and commercial spaces, including polishing, staining, and crack repair.
Their experienced teams ensure workmanship that stands the test of time and looks exceptional too.
Trusted Experience and Community Recognition Mitchell learned the trade from his father and, since 2014, has applied that family craftsmanship across hundreds of projects in Waterloo, Cambridge, Kitchener, and beyond. The company consistently delivers projects on time and within budget, earning praise for both skill and client service.
Customer testimonials reflect satisfaction in quality, punctuality, cleanliness, and professionalism-particularly on tight schedules and complex work.
Reliable Results with a Personal Touch Mitchell Blackwell Parging & Masonry balances industrial-grade results with a personal, family-driven touch. Regardless of project size, their goal remains the same: to execute with care, communicate clearly, and make each customer feel respected.
They serve both residential and commercial clients, ensuring that materials, ornamental details, and structural improvements align with the client’s vision and the property’s needs.
Commitment That Builds Trust Winning the Consumer Choice Award reflects the trust that homeowners and businesses across Waterloo Region have placed in Mitchell Blackwell Parging & Masonry Inc. This recognition reinforces the company’s dedication to quality, reliability, and craftsmanship in every project they undertake.
“This award validates our dedication to quality and community,” says Mitchell. “We’re grateful for the trust our clients show us-and we’re committed to building stronger foundations for the region.”
About Mitchell Blackwell Parging & Masonry Inc. Coming from a bricklaying family, Mitchell is hands-on in every project, and his crew of skilled tradespeople reflects that same passion and expertise. Their gallery of past work includes foundations, chimneys, patios, and epoxy floors that showcase both functionality and aesthetic appeal.
About Consumer Choice Award: Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.
OTTAWA, ON / ACCESS Newswire / August 13, 2025 / Westend Academy (Ottawa School of Beauty Ltd), a locally owned and operated beauty school, has won the 2025 Consumer Choice Award in the School – Hair Styling & Esthetics category for Ottawa. This recognition reflects the school’s long-standing commitment to excellence in beauty education, empowering students to build rewarding careers in hairstyling, esthetics, and medical spa services.
With campuses in Ottawa and London, Ontario, Westend Academy has earned a reputation as a top-tier cosmetology institution offering full-time OSAP-eligible diploma programs. The Academy specializes in hands-on, real-client salon and spa training that prepares graduates to enter the workforce confident, experienced, and job-ready.
Award-Winning Education Backed by Experience
Founded in 1998, Westend Academy provides students with real-world learning environments that mimic professional settings. Students perform services for paying clients under the guidance of experienced instructors, gaining the technical skills, client service abilities, and speed that today’s employers demand.
“We pride ourselves on producing graduates who are well-trained, adaptable, and ready to contribute on day one,” says the Westend Academy team. “This award reflects the dedication of our instructors and the success of our students.”
Small Class Sizes, Personalized Mentorship
Westend Academy maintains a low student-to-instructor ratio, allowing for more personalized feedback and mentorship. With expert instructors like Phil Weaver (Executive Director with 30+ years in the salon industry), Terry Ralph (Barbering & Hairstyling instructor since 2003), and Mira Dayfallah (Medical Esthetics instructor with 20+ years of experience), students are guided by professionals who bring deep industry knowledge and passion to the classroom.
Programs Designed for Career Success
The Academy offers comprehensive training across multiple programs:
Professional Hairstyling
Barbering
Esthetics & Advanced Skin Care
Medical Esthetics & Spa Therapies
Courses are continuously updated to match the demands of the beauty and wellness industry, integrating the latest tools, digital resources, and product innovations. Students train with industry-leading equipment and multimedia instruction, preparing them for a range of careers in beauty, wellness, and spa management.
Hands-On Experience That Makes a Difference
From the first week of class, students work in Westend Academy’s operational salon and spa clinics-gaining real experience with clients in haircuts, coloring, skincare, waxing, massage, facials, laser treatments, and more. This immersive approach not only improves technical proficiency but helps students build speed, confidence, and professionalism before they graduate.
Job Placement & Continued Support
Graduates benefit from the Academy’s strong industry network and dedicated Job Connect program, which helps place students in salons, spas, and medi-spa clinics across Ontario. Alumni frequently return to share success stories or hire future grads, reinforcing the school’s strong community ties.
For entrepreneurial students, Westend Academy offers guidance in salon ownership, branding, and customer management-empowering future beauty professionals to become business leaders.
Accessible, Supported Learning
All diploma programs are eligible for OSAP, and the Academy offers tuition payment plans and financial aid options. As a registered career college under the Ontario Career Colleges Act, Westend Academy ensures its programs meet high standards in both academic and hands-on training.
Commitment That Builds Careers
The 2025 Consumer Choice Award reflects the trust Ottawa students and families place in Westend Academy’s training model. With more than 25 years of success and thousands of alumni in the field, the school remains committed to building confident, skilled professionals who are ready to make their mark.
“This recognition means everything to us,” the team says. “It represents the trust our students and community place in our school, and we’ll continue to raise the bar for beauty education in Ottawa and beyond.”
About Westend Academy: Westend Academy (Ottawa School of Beauty Ltd) is a leading beauty school offering diploma programs in hairstyling, barbering, esthetics, and medical esthetics. With two campuses in Ottawa and London, the Academy delivers hands-on, real-client training in a professional environment. Westend Academy is registered under the Ontario Career Colleges Act and offers OSAP-eligible programs, small class sizes, and strong career placement support. To learn more about Westend Academy’s award-winning programs, visit beautyacademy.ca or explore their CCA Page.
About Consumer Choice Award: Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.
